Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
PRX-PLUS has a unique product feature with its deep-impacting formula
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The freshly infused capital will primarily be deployed towards expansion and research & development
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Subscribe To Our Newsletter & Stay Updated